HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells

Autor: Lu Wen, Frank I. Comer, Michael Oberst, Mary Jane Hinrichs, Tao Zhang, Alfred E. Chang, Yangyi Bao, Yuanyuan Liu, Hannah E. Dobson, Steven R. Coats, Qiao Li, Max S. Wicha, Fu Dai, You Qin, Leiming Xia
Rok vydání: 2021
Předmět:
Zdroj: Cell Chem Biol
ISSN: 2451-9456
Popis: We previously tested HER2-targeted antibody drug conjugates (ADC) in immunocompromised (SCID) mice, precluding evaluation of host immunity, impact on cancer stem cells (CSCs), and potential benefit when combined with PD-L1 blockade. In this study, we tested HER2-targeted ADC in two immunocompetent mouse tumor models. HER2-targeted ADC specifically inhibited the growth of HER2-expressing tumors, prolonged animal survival, and reduced HER2(+) and PD-L1(+) cells. ADC plus anti-PD-L1 antibody augmented therapeutic efficacy, modulated immune gene signatures, increased the number and function of CD3(+) and CD19(+) tumor-infiltrating lymphocytes (TILs), induced tumor antigen specific immunological memory, stimulated B cell activation, differentiation, and IgG1 production both systemically and in the tumor microenvironment. In addition, ADC therapy modulated T cell subsets and their activation in TILs. Furthermore, HER2-targeted ADC reduced the number and tumorigenicity of ALDH(hi) CSCs. This study demonstrates that HER2-targeted ADC effectively targets ALDH(hi) CSCs and this effect is augmented by co-administration of anti-PD-L1 antibody.
Databáze: OpenAIRE